Humacyte, Inc. is starting a public offering of common stock on Nasdaq

From GlobeNewswire: 2025-03-25 16:01:00

Humacyte, Inc. has started an underwritten public offering of its common stock on Nasdaq under the ticker symbol HUMA. The company plans to grant underwriters an option to purchase additional shares. The net proceeds from the offering will be used for commercializing SYMVESS™ in vascular trauma, developing other product candidates, and general corporate purposes. The offering is led by TD Cowen, Barclays, and BTIG, with H.C. Wainwright & Co. and The Benchmark Company as lead managers. The offering’s completion is subject to market conditions. The ATEV from Humacyte is currently in late-stage clinical trials for various vascular applications.



Read more at GlobeNewswire: Humacyte, Inc. Announces Proposed Public Offering of Common